MedPath

Johnson & Johnson Showcases Neuropsychiatry Innovations at Psych Congress

Johnson & Johnson presents new data on SPRAVATO® and its neuropsychiatry portfolio at the U.S. Psychiatric and Mental Health Congress, highlighting long-term safety and efficacy in treating treatment-resistant depression and schizophrenia.

At the annual U.S. Psychiatric and Mental Health Congress (Psych Congress), Johnson & Johnson (J&J) is set to present 23 abstracts featuring new real-world and clinical trial data from its neuropsychiatry portfolio and pipeline. Key highlights include new five-year data reinforcing the long-term safety and efficacy of SPRAVATO® (esketamine) in patients with treatment-resistant depression (TRD), and insights into the clinical, humanistic, and economic burden of anhedonia in adults with major depressive disorder (MDD).
SPRAVATO®, a CIII nasal spray, is approved by the U.S. Food and Drug Administration for use in combination with an oral antidepressant for adults with TRD and depressive symptoms in adults with MDD with acute suicidal ideation or behavior. The presentations also include a large real-world analysis highlighting the link between reducing relapse and improving survival in schizophrenia.
J&J's commitment to neuroscience innovation is evident in its robust portfolio and pipeline, aimed at addressing the significant unmet needs of patients with serious mental illnesses. The company's presentations at Psych Congress underscore its dedication to advancing research and understanding of MDD and schizophrenia, with the goal of delivering transformational therapies.
Key presentations include:
  • New five-year, real-world safety data from nearly 35,000 adults treated with SPRAVATO®.
  • Novel insights into the burden of anhedonia in adults with MDD.
  • Results from an analysis of more than 30,000 adults with schizophrenia, emphasizing the link between symptom relapse and risk of death.
J&J's neuropsychiatry portfolio also includes long-acting injectables (LAIs) for schizophrenia, such as INVEGA SUSTENNA®, INVEGA TRINZA®, and INVEGA HAFYERA®, which offer varied dosing options and are recognized for their role in controlling symptoms and reducing costly relapses.
The Psych Congress serves as a platform for J&J to share its latest research findings and reinforce its position as a leader in neuroscience, committed to improving the lives of those affected by challenging-to-treat mental illnesses.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

6% of Seniors Depressed; ADHD and Hormones; Novel Antipsychotic Eases Schizophrenia

Recent studies highlight various aspects of mental health, including depression in seniors, the impact of hormones on ADHD symptoms, and the effectiveness of a novel antipsychotic in treating schizophrenia. A study found that 6% of older adults suffer from depression, with higher rates among women, the unmarried, and those with chronic conditions. Another study suggested that ADHD symptoms may fluctuate with hormonal changes. Additionally, a phase II trial showed that a new antipsychotic, LB-102, significantly improved schizophrenia symptoms.

Roluperidone Shows Promise in Treating Negative Symptoms of Schizophrenia

Roluperidone, currently in Phase 3 trials, offers hope for treating schizophrenia's negative symptoms by blocking serotonin rather than dopamine.
Clinical data suggests Roluperidone improves global functioning in schizophrenia, primarily by reducing avolition, a key negative symptom.

FDA to Review Rexulti for PTSD Treatment Amidst PDUFA Delay

The FDA will convene a Psychopharmacologic Drugs Advisory Committee (PDAC) to review Rexulti (brexpiprazole) in combination with sertraline for treating PTSD in adults.
The FDA's decision to host a PDAC meeting indicates a delay in the Prescription Drug User Fee Act (PDUFA) target action date, originally set for February 8, 2025.

Seaport Therapeutics' SPT-300 Shows Promise in Phase I Trial for Neurological Conditions

Seaport Therapeutics' SPT-300, an allopregnanolone prodrug, demonstrates good tolerability in a Phase I trial with 99 healthy volunteers, highlighting its safety profile.
The study observed therapeutically relevant blood levels of SPT-300, up to nine times greater than orally administered unmodified allopregnanolone, suggesting enhanced bioavailability.

New Wave of Depression Meds Target Novel Mechanisms Beyond Serotonin

Johnson & Johnson's Spravato, an esketamine-based nasal spray, marked the first new depression medication in decades, offering a more rapid treatment option than traditional SSRIs.
Psychiatric drug development is experiencing a resurgence, with over 160 medications for mental health conditions in the pipeline, targeting more precise diagnoses and nuanced treatments.

Olanzapine LAI Shows Promise in Schizophrenia Treatment with Improved Safety Profile

Phase III data for TEV-'749, an olanzapine long-acting injectable (LAI), demonstrates significant improvement in social functioning and quality of life for schizophrenia patients.
TEV-'749 shows no incidents of post-injection delirium/sedation syndrome (PDSS), a major barrier for existing olanzapine LAIs due to FDA black box warning.

Teva's TEV-'749 Shows Promise in Improving Social Functioning in Schizophrenia Patients

Teva's TEV-'749, a subcutaneous olanzapine injection, demonstrated significant improvements in social functioning and quality of life in schizophrenia patients in the Phase 3 SOLARIS trial.
The SOLARIS trial showed statistically significant improvements in Personal and Social Performance Scale scores with TEV-'749 compared to placebo (p<0.05) across multiple doses.

Teva's TEV-'749 Shows Promise in Improving Social Functioning in Schizophrenia Patients

Teva's TEV-'749, a subcutaneous long-acting injectable olanzapine, demonstrated significant improvements in social functioning and quality of life in adults with schizophrenia in the Phase 3 SOLARIS trial.
The SOLARIS trial showed statistically significant improvements in the Personal and Social Performance Scale and Schizophrenia Quality of Life Scores compared to placebo.

Supernus' SPN-820 Shows Promise as Rapid-Onset Depression Treatment

Supernus Pharmaceuticals' SPN-820, a novel mTORC1 modulator, demonstrated safety and efficacy as an adjunctive treatment for major depressive disorder in a Phase IIa trial.
The trial indicated SPN-820's potential for rapid-onset response in adults with depression, addressing a critical need for faster-acting antidepressants.

Atomoxetine Evaluated for Apathy and Impulsivity in Progressive Supranuclear Palsy

The NORAPS phase 2 trial is assessing atomoxetine, a noradrenaline reuptake inhibitor, for treating apathy and impulsivity in progressive supranuclear palsy (PSP).
The double-blind, randomized crossover study will evaluate 40 mg of atomoxetine against a placebo, with a target enrollment of 84 participants across multiple sites.

Reference News

[1]
Johnson & Johnson highlights innovative neuropsychiatry ...
morningstar.com · Oct 24, 2024

Johnson & Johnson presents new data at Psych Congress, highlighting SPRAVATO®'s long-term safety and efficacy for treatm...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy